Yes, you should receive Shingrix before starting Icotyde (risankizumab)
You should get the Shingrix vaccine before initiating Icotyde, ideally completing both doses (given 2-6 months apart) prior to starting the biologic therapy. This recommendation is based on FDA labeling for Icotyde which explicitly advises avoiding live vaccines during treatment and completing immunizations according to current guidelines before therapy initiation 1, combined with EULAR guidelines recommending vaccination preferably 4 weeks prior to starting biologic DMARDs 2.
Why Vaccinate Before Starting Icotyde
Icotyde (risankizumab) is an immunosuppressive biologic that increases infection risk. The FDA label specifically states to "complete immunizations according to current immunization guidelines" prior to initiating therapy and to "avoid use of live vaccines in patients during treatment" 1. While Shingrix is a non-live recombinant vaccine (making it safe even during immunosuppression), vaccinating before starting Icotyde ensures:
- Optimal immune response: Your immune system will be fully functional to mount the best antibody and cellular responses to the vaccine
- Maximum protection: Herpes zoster risk is significantly elevated in patients on immunosuppressive therapies
- Reduced complications: Shingrix is 73.9% effective against herpes zoster and 83.7% effective against postherpetic neuralgia in real-world data 3
Vaccination Schedule
Complete the full 2-dose Shingrix series:
- First dose: As soon as possible
- Second dose: 2-6 months after the first dose 4
- Ideally wait 4 weeks after completing the vaccine series before starting Icotyde 2
If timing is urgent and you cannot wait for both doses, you can receive the first dose and start Icotyde, then complete the second dose while on therapy. Shingrix is a non-live vaccine, so it remains safe during immunosuppression 2.
Evidence Supporting This Approach
The 2019 EULAR guidelines specifically address this scenario, noting that the recombinant zoster vaccine (Shingrix) "may replace the live-attenuated vaccine in patients with AIIRD" and is recommended for immunosuppressed patients 2. Recent data shows:
- 50% effectiveness in patients with inflammatory arthritis on immunomodulatory treatment 5
- Persistent protection for up to 4 years post-vaccination 3
- Safety profile: No increased serious adverse events compared to placebo in immunocompromised populations 6
- Immunogenicity maintained: Even in patients on biologics, though slightly reduced compared to immunocompetent individuals 6, 7
Important Caveats
Local and systemic reactions are common with Shingrix (more than placebo), including injection site pain, fatigue, myalgia, and headache 6, 8. These are temporary and resolve within days. This should not deter vaccination, as the benefits far outweigh these transient side effects.
If you must start Icotyde urgently and cannot complete both Shingrix doses beforehand, get at least the first dose before starting therapy. One dose provides 60.3% protection against herpes zoster 3, which is better than no protection. Complete the second dose as soon as feasible (within 2-6 months) even while on Icotyde.
Post-herpes zoster cardiovascular risk: Data shows increased risk of venous thromboembolic events 60-90 days after herpes zoster infection 5, providing additional rationale for prevention through vaccination.